Abstract: A three-dimensional display device includes a display, a barrier, and a controller. The display displays a parallax image including a right-eye viewing image and a left-eye viewing image. The barrier defines a traveling direction of image light of the parallax image. The controller causes a black image to appear between the right-eye viewing image and the left-eye viewing image based on a parallax value of the parallax image.

Abstract: An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

Abstract: Provided are sodium hypochlorite pentahydrate crystals capable of long-term storage that have improved stability of sodium hypochlorite pentahydrate, which is effective as an oxidizing 5 agent or bactericide, in the vicinity of normal temperatures, and a method for producing the same. The sodium hypochlorite pentahydrate crystals are such that peaks appear at the locations of the angles of diffraction described in Table 1 of claim 1 over a range of 10°?2? (angle of diffraction)?65° as measured by powder X-ray diffraction using a Cuk? radiation source.

Abstract: The present invention aims to provide a material for adsorbing soluble tumor necrosis factor receptors with high efficiency. The present invention provides an adsorbing material for soluble tumor necrosis factor receptors, which includes a superficially porous water-insoluble polymeric material, wherein the pore size distribution curve for the surface of the water-insoluble polymeric material, which is derived from a distribution of melting points determined by differential scanning calorimeter, shows the peak radius in the range of 1 to 80 nm, and the water-insoluble polymeric material has a zeta potential at pH 7.4 of ?15 to 15 mV, and the water-insoluble polymeric material is in fiber, particle, or film form.

Abstract: An object of the present invention is to provide a carrier for adsorbing organic matter, which achieves both of adsorption ability for organic matter and suppression of pressure increase. The present invention provides a carrier for adsorbing organic matter, comprising a sea-island type solid composite fiber, wherein the pore volume is 0.05 to 0.5 cm3/g and the fiber diameter is 25 to 60 ?m.

Abstract: An object of the present invention is to provide a carrier for adsorbing organic matter, which achieves both of adsorption ability for organic matter and suppression of pressure increase. The present invention provides a carrier for adsorbing organic matter, comprising a sea-island type solid composite fiber, wherein the pore volume is 0.05 to 0.5 cm3/g and the fiber diameter is 25 to 60 ?m.

Abstract: The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.

Abstract: The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.

Abstract: An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

Abstract: An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

Abstract: An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

Abstract: Provided are sodium hypochlorite pentahydrate crystals capable of long-term storage that have improved stability of sodium hypochlorite pentahydrate, which is effective as an oxidizing agent or bactericide, in the vicinity of normal temperatures, and a method for producing the same. The sodium hypochlorite pentahydrate crystals are such that peaks appear at the locations of the angles of diffraction described in Table 1 of claim 1 over a range of 10°?2? (angle of diffraction)?65° as measured by powder X-ray diffraction using a CuK? radiation source.

Abstract: Provided are sodium hypochlorite pentahydrate crystal gains that have high bulk density and increase bulk density in a container and improve transport efficiency by controlling the shape of the sodium hypochlorite pentahydrate crystals, and a production method thereof. As a result of stirring or circulating by pump an aqueous solution of sodium hypochlorite pentahydrate in a crystallization tank in a crystallization step, sodium hypochlorite pentahydrate crystal grains are obtained having an average aspect ratio of 2.5 or less.

Abstract: An adsorption carrier-packed column includes a central pipe, adsorption carrier, plate A, and plate B, wherein an insertion material C is inserted between the adsorption carrier and the plate A; an insertion material D is inserted between the adsorption carrier and the plate B; the ratio of the deformation rate of the insertion material C (C1) to the deformation rate of the adsorption carrier (E0) is 1<C1/E0<10, and the ratio of the deformation rate of the insertion material D (D1) to the deformation rate of the adsorption carrier (E0) is 1<D1/E0<10; and the ratio of the thickness of the insertion material C (TC) to the distance of a gap between the adsorption carrier and the plate A (LA) is 1.1<TC/LA<4, and the ratio of the thickness of the insertion material D (TD) to the distance of a gap between the adsorption carrier and the plate B (LB) is 1.1<TD/LB<4.

Abstract: The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR-1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

Abstract: This invention relates to 4-{[4-({([4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]-oxy}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid for use in therapeutic treatment of the human body. In particular, it relates to the compound having selective 5-HT4 receptor agonism, which is useful for treating gastroparesis, or preventing or delaying the onset or the progression of gastroparesis.

Abstract: The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR-1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSRla receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

Abstract: This invention relates to 4-{[4-({([4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]-oxy}methyppiperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid for use in therapeutic treatment of the human body. In particular, it relates to the compound having selective 5-HT4 receptor agonism, which is useful for treating gastroparesis, or preventing or delaying the onset or the progression of gastroparesis.